Silence Therapeutics
{{Use dmy dates|date=April 2022}}
{{advert|date=January 2022}}
{{Infobox company|
| name = Silence Therapeutics PLC
| logo = Silence_Therapeutics_logo.png
| type = Public ({{Nasdaq|SLN}})
| foundation = 1994
| hq_location = Hammersmith, London
| industry = Pharmaceuticals
| num_employees = 120
| homepage = [http://www.silence-therapeutics.com/ www.silence-therapeutics.com]
}}
Silence Therapeutics (Nasdaq: SLN{{cite web|title=Google Finance Stock Exchange listing for Silence Therapeutics|url=https://finance.yahoo.com/quote/SLN?p=SLN&.tsrc=fin-srch}}) is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.{{cite web |title=About us |url=https://silence-therapeutics.com/about-us/default.aspx |website=silence-therapeutics.com |access-date=26 June 2023 |archive-url=https://web.archive.org/web/20230326025827/https://silence-therapeutics.com/about-us/default.aspx |archive-date=Mar 26, 2023 |language=en |url-status=live}}
Development
Silence Therapeutics develops medicines related to RNA interference or RNAi to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet needs. Silence's mRNA GOLD platform can be used to create siRNAs (short interfering RNAs) that target and silence disease-associated genes in the liver.{{Cn|date=August 2024}}
Silence Therapeutic's product candidates include SLN124 for hematological diseases{{Cn|date=August 2024}} and zerlasiran (formerly SLN360) for reducing cardiovascular risk in people born with high levels of lipoprotein(a),{{Cn|date=August 2024}} a genetic risk factor for cardiovascular disease. The company reported in November 2023 that a phase 1 study showed injection of repeated doses reduced patients' baseline of Lp(a) by up to 99 per cent for 90 days after.{{Cite web |last= |date=2023-11-10 |title=Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease |url=https://www.dicardiology.com/content/silence-therapeutics-announces-positive-topline-results-phase-1-multiple-dose-study |access-date=2024-08-23 |website=DAIC |language=en}}
Partnerships
Silence Therapeutics is under the stewardship of CEO Craig Tooman, and has established partnerships with pharmaceutical companies, such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.{{Cite web |last= |date=2023-01-12 |title=Transcript : Silence Therapeutics plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 09 |url=https://www.marketscreener.com/quote/stock/SILENCE-THERAPEUTICS-PLC-111895683/news/Transcript-Silence-Therapeutics-plc-Presents-at-41st-Annual-J-P-Morgan-Healthcare-Conference-Jan-42723006/ |access-date=2024-08-23 |website=MarketScreener |language=en}}
References
{{Reflist}}
External links
- [http://www.silence-therapeutics.com/ Official website]
{{Pharmaceutical and biotechnology industry in the United Kingdom}}
{{Pharmaceutical companies of the United States}}
{{Authority control}}
Category:Pharmaceutical companies of England
Category:Medical and health organisations based in England
Category:Companies based in the London Borough of Hammersmith and Fulham